ALK-negative anaplastic large cell lymphoma
GPTKB entity
Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:associated_with |
gptkb:non-Hodgkin_lymphoma
skin lesions molecular profiling treatment resistance cytogenetic abnormalities elevated LDH levels bone marrow involvement secondary malignancies increased risk of secondary cancers high risk of transformation CNS involvement potential for transformation to more aggressive forms B symptoms clinical heterogeneity extranodal disease multidisciplinary management approach need for long-term follow-up poor prognosis in some cases potential for late effects from treatment relatively aggressive behavior |
| gptkbp:clinical_trial |
ongoing studies
combination therapies being evaluated immunotherapy approaches being tested new therapies under investigation targeted therapies being explored |
| https://www.w3.org/2000/01/rdf-schema#label |
ALK-negative anaplastic large cell lymphoma
|
| gptkbp:is_associated_with |
T P53
C D15 C D30 |
| gptkbp:is_characterized_by |
absence of ALK gene rearrangement
|
| gptkbp:is_often_used_in |
adults
|
| gptkbp:risk_factor |
viral infections
immune system disorders |
| gptkbp:social_responsibility |
rare
variable more common in males biopsy flow cytometry immunohistochemistry incidence rate varies by region |
| gptkbp:symptoms |
weight loss
fever lymphadenopathy |
| gptkbp:treatment |
radiation therapy
chemotherapy relapse remission stem cell transplant |
| gptkbp:type_of |
gptkb:healthcare_organization
|
| gptkbp:bfsParent |
gptkb:anaplastic_large_cell_lymphoma,_ALK-negative
|
| gptkbp:bfsLayer |
6
|